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Advances in basic hepatology have been constrained for many
years by the inability to culture primary hepatocytes in vitro,
until just over ﬁve years ago when the scientiﬁc playing ﬁeld
was changed beyond recognition with the demonstration that
human skin ﬁbroblasts could be reprogrammed to resemble
embryonic cells. The reprogrammed cells, known as induced plu-
ripotent stem cells (iPSCs), were then shown to have the capacity
to re-differentiate into almost any human cell type, including
hepatocytes. The unlimited number and isogenic nature of the
cells that can be generated from tiny fragments of tissue have
massive implications for the study of human liver diseases
in vitro. Of more immediate clinical importance were recent data
demonstrating precision gene therapy on patient speciﬁc iPSCs,
which opens up the real and exciting possibility of autologous
hepatocyte transplantation as a substitute for allogeneic whole
liver transplantation, which has been an effective approach to
end-stage liver disease, but one that has now been outstripped
by demand. In this review, we describe the historical develop-
ment, current technology and potential clinical applications of
induced pluripotency, concluding with a perspective on possible
future directions in this dynamic ﬁeld.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.• Shinya Yamanaka and Sir John Gurdon were recently
awarded the nobel prize for their work on induced
pluripotent stem cells (iPSCs)
• iPSCs have the capacity to generate unlimited
quantities of any cell type in the human body
• Since their discovery five years ago, numerous studies
suggest this new technology could soon be used to
generate novel, patient specific in vitro disease models
and transplantation products 
• One of the first disease areas to benefit from this
exciting new resource is likely to be HepatologyHistory of iPSCs
For many, the story of iPSCs began almost 60 years ago. Semi-
nal experiments in the early 1960s carried out by Briggs and
King in Philadelphia and Gurdon in Cambridge, described trans-
plantation of donor tadpole intestinal cell nuclei into recipient
enucleated frog eggs [1]. Transplanted eggs grew into living
tadpoles genetically identical to the donor nucleus, leading to
the hypothesis that the host egg cytoplasm had somehow con-
verted the transplanted nucleus into a cell capable of forming
an entire healthy adult frog (Fig. 1). It was concluded that an
unknown myriad of factors present in the egg cytoplasm must
have ‘reprogrammed’ the phenotype of a fully differentiatedJournal of Hepatology 20
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E-mail address: str29@cam.ac.uk (S.T. Rashid).adult cell back into a totipotent one-cell-stage embryo. This
experimental procedure was given the term ‘somatic cell
nuclear transfer’ and by the mid 1990s had been applied to
several mammalian species, most famously resulting in the
cloning of ‘Dolly’ the sheep [2]. These experiments suggested
Gurdon’s earlier hypothesis that the pliability of adult cells sec-
ondary to epigenetic (non-genetic) factors was not only appli-
cable in simple organisms such as the frog, but also held
true for complex mammals such as sheep. Indeed the possibil-
ity that these principles may be at play in human cells formed
the ideological basis for Yamanaka’s landmark study in 2006.
Yamanaka reasoned that enforced expression of a limited num-
ber of genes, critical to the maintenance of pluripotency in
embryonic stem cells (ESCs), might enable direct reprogram-
ming of somatic cells without the need for nuclear transfer
[3]. By a process of stepwise elimination, just four transcription
factor genes (Oct3/4 (Pou5f1), Sox2, Klf4, and Myc) were eventu-
ally identiﬁed as sufﬁcient to give rise to the newly formed
pluripotent cells and the term ‘‘induced pluripotent stem cells’’
(iPSCs) was born (Fig. 1). These landmark advances in basic cell
biology were celebrated by the recent award of the Nobel Prize
for Physiology and Medicine to Professors Gurdon and
Yamanaka.13 vol. 58 j 625–629
• To realize this clinical promise, several key challenges
surrounding the reproducibility and epigenetic/genetic
stability of the products will first need to be addressed
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Fig. 1. Derivation of pluripotent stem cells. Pluripotent stem cells, possessing the ability to form any cell type of the human body, can be created using in vitro fertilisation
(Steptoe and Edwards), somatic cell nuclear transfer (Gurdon), and transcription factor overexpression (Yamanaka).
Clinical Application of Basic ScienceHow have iPSCs been used so far?
Disease modelling
Following the ﬁrst human ﬁbroblast derivation of iPSCs, investi-
gators went on to show that the reprogramming protocol could
be used in cells taken from patients with a wide range of Mende-
lian and complex genetic disease backgrounds [4]. These observa-
tions were then followed-up by studies proving that human iPSCs
could be differentiated into adult-like somatic cells. A range of
different cells with varying relevant functional properties have
since been generated including motor and dopaminergic neurons,
cardiac cells, pancreatic cells, adipocytes, blood cells, vascular
cells, retinal progenitors, and liver cells [5]. Importantly, several
laboratories have also now shown that such patient speciﬁc
hIPSC-derived somatic cells can be used to generate exciting
new in vitro disease models. Examples of diseases modelled in
this way include LEOPARD syndrome, Long QT/Timothy syn-
dromes, RETT syndrome, and Hutchinson–Gilford progeria [6].
Within the liver ﬁeld, we recently demonstrated dermal ﬁbro-
blasts obtained from patients suffering from ﬁve of the ‘‘inherited
metabolic liver disorders’’ (a1-antitrypsin deﬁciency, glycogen
storage disease type 1a, familial hypercholesterolaemia, heredi-
tary tyrosinaemia, and Crigler–Najjar syndrome) could be used
to generate patient speciﬁc human iPSC lines [7]. Each of the
human iPSC lines was then differentiated into hepatocyte-like
cells using a novel three-step differentiation protocol in chemi-
cally deﬁned conditions. The cells were assessed for in vitro func-
tion, ability to replicate key features of disease pathology, and
response to targeted small molecules. Patient speciﬁc human
iPSC-derived hepatocytes with in vitro function approximating
adult human hepatocytes exhibited key pathological features of
the diseases from which they were derived, most notably protein
misfolding in the ER, deﬁcient receptor-mediated extracellular
lipid uptake and impaired enzyme dependent cellular metabo-
lism. Whilst hIPSC-derived hepatocytes possess functionality
approximating their primary hepatic counterparts, they are still626 Journal of Hepatology 201far from being identical with respect to activities such as cyto-
chrome P450 activity. This drawback may not present a problem
for the modelling of inherited monogenetic disorders [7,8], but
may stunt efforts to apply this technology for use with drug tox-
icology and viral hepatitis studies [9]. (The topic of human iPSC-
based disease modelling is reviewed more extensively by Wu and
Hochedlinger [10] and Robinton and Daley [6].)
Regenerative medicine
Human trials using iPSCs have not yet been started. This is not
altogether surprising since when we consider that human ESC
products, despite their longer history, are only now entering into
clinical trials. A phase I study based on the use of human ESC-
derived retinal pigment epithelium for macular degeneration,
for example, recently demonstrated no adverse side effects asso-
ciated with therapy [11]. Such advances suggest it will only be a
matter of time before iPSC-based trials are also conducted.
The complex biological interactions that might account for
positive results in regenerative medicine trials suggest to many
that this type of therapy may not be easily translatable across dif-
ferent organ systems. Cell-based therapies for well-characterised
monogenetic disorders that affect single adult cell types, how-
ever, will probably prove an easier and more realistic ﬁrst target
for such trials. As such, inherited liver disorders would appear to
be one such credible ﬁrst target. Several animal models have
already demonstrated that transplanted wild type hepatocytes
possess a selective survival advantage over genetically mutated
host cells [12]. Though translation of such studies into humans
has proven disappointing [13], this lack of clinical success is
attributed to the scarcity of high-quality cells and continued
requirement for life-long immunosuppression.
Using patient speciﬁc hiPSC-derived heaptocytes to treat
monogenetically inherited liver disorders could overcome these
problems. Importantly, correction of the underlying genetic
abnormality in a manner fully compatible with clinical applica-
tions would ﬁrstly be required. Since the most widely validated3 vol. 58 j 625–629
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Fig. 2. Using iPSCs for human therapy. Patient speciﬁc skin samples are ﬁrstly reprogrammed into iPSCs. Genetic diseases could then be treated by editing the genomes of
iPSCS, differentiating them into target adult cells, and ﬁnally transplanting the corrected cells back into the original patient.
JOURNAL OF HEPATOLOGYmethodology of gene correction (homologous recombination) is
relatively inefﬁcient in human pluripotent stem cells, other strat-
egies to achieve gene therapy in hIPSCs have been evaluated.
Considerable interest has been directed towards the use of Zinc
Finger Nuclease (ZFN) technology, and has been shown to stimu-
late gene targeting in human ESCs and iPSCs [14]. ZFNs are a
designed, sequence speciﬁc endonuclease that can be customised
to cleave a user-chosen DNA target (reviewed in [18]). Current
methods for gene targeting rely on positive selection to isolate
rare clones that have undergone homologous recombination. To
remove the unwanted selection cassettes, Cre/loxP or Flp/FRT
recombination systems are used, which leave behind single loxP
or FRT sites. These small ectopic sequences have the potential
to interfere with transcriptional regulatory elements of surround-
ing genes, most of which are not fully characterised in the human
genome. An alternative method is to remove selection cassettes
by converting them into transposons. The most suitable transpo-
son for this purpose is piggyBac, a moth-derived DNA transposon,
which can transpose efﬁciently in mammalian cells including
human ESCs. A remarkable feature of this mobile element is
seamless excision, which enables removal of transgenes ﬂanked
by piggyBac inverted repeats without leaving any residual
sequences, thus making it clinically suitable [15].
We recently exploited these advances in hIPSC, ZFN, and pig-
gyBac technology to achieve correction of the genetic defect
responsible for PiZ a1-antitrypsin deﬁciency (Glu342Lys) in
patient speciﬁc human iPSCs [16] (Fig. 2). By this approach, we
demonstrated, for the ﬁrst time, an efﬁcient gene editing tech-
nique capable of restoring normal structure, function, and secre-
tion of a1-antitrypsin in derived liver cells. Lines wereJournal of Hepatology 201characterised not only at the chromosome number level (by G-
banding), but also for copy number variation (using array-based
comparative genomic hybridization (aCGH)) and single base pair
resolution (using whole exome sequencing). A large proportion of
reprogrammed human iPSCs carried the correct number of chro-
mosomes but had signiﬁcant copy number variation detected by
aCGH. Lines genetically stable by aCGH could be identiﬁed and
these were subjected to whole exome sequencing. This analysis
revealed that whilst the gene correction technique did not per-
turb the genome, the initial derivation of human iPSC lines
induced 29 exomic point mutations. The biological relevance of
such point mutations in iPSC-derived hepatocytes is unclear at
present. None of the new mutations occurred in genes known
to predispose to cancer. Moreover, to the best of our knowledge,
such an in-depth analysis of human cell lines has not previously
been performed. We therefore investigated the behaviour of the
cells in vivo by injecting genetically corrected iPSC-derived liver
cells into a mouse model of liver injury. This assay conﬁrmed
the functional capacity of the cells and, importantly, demon-
strated that the point mutations did not induce catastrophic car-
cinogenic sequelae since none of the mice developed tumours. In
total, these results provided proof of principle for the potential of
combining human iPSCs with gene therapy techniques to gener-
ate cells for autologous cell-based treatment of individuals with
a1-antitrypsin deﬁciency.
Future challenges
Several challenges remain before this technology could be
applied within the context of a clinical trial. The biggest concern3 vol. 58 j 625–629 627
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for all undoubtedly remains the potential risk of inducing cancer.
This risk in itself could manifest as a consequence of one of sev-
eral possibilities. Firstly, if undifferentiated pluripotent stem cells
somehow contaminate the transplanted hepatocyte cell popula-
tion, teratoma formation is the likely consequence. Identifying
precise cell surface markers to efﬁciently purify populations from
these contaminants, possibly through ﬂow sorting techniques,
could solve this problem, and has recently been reported [17].
Further work to conﬁrm this encouraging preliminary data is
now needed. Secondly, puriﬁed iPS-derived hepatocytes may
themselves be oncogenic. This may be a consequence of repro-
gramming induced genetic changes or aberrant epigenetic hot-
spots within the genome [18]. Though researchers are actively
engaged in trying to understand the mechanisms for such obser-
vations, nothing deﬁnitive has so far come to light. As the cost of
whole genome assays comes down, it could be envisaged that
banks of candidate cell lines are genetically analysed before only
the ‘‘cleanest’’ cells cherry-picked for further investigation within
the context of large animal transplantation models prior to
human trials. Further epigenetic modiﬁcations, to ensure com-
plete reprogramming, may also be necessary or alternatively, pri-
mary cells for reprogramming sourced from only the same
lineage as the target cell of transplantation [19].
Finally, cellular transplantation may induce oncogenicity in
cells residing within the transplanted niche, via an undeﬁned
mechanism, though possibly as a result of disrupted immunolog-
ical homeostasis [20]. Tackling the issue of immune rejection
seems the most challenging, given the current lack of an appro-
priate model. One solution may involve the creation of popula-
tion-based iPSC banks which could then be used in a similar
way to blood transfusion banks [21].
So long as iPSC-derived hepatocytes can be shown to be free
from major complications at this stage, however, a move towards
clinical trials would appear rational. At this point, several other
challenges will then need to be addressed, such as route, dosage,
and technique of administration, and the ﬁnancial costs associ-
ated with generating cells in GMP conditions. Perhaps the biggest
concern for stem cell biologists, however, centres around the bio-
logical functionality of the cell type produced in vitro. Data from
the wider iPS ﬁeld suggests cell types currently being produced
in vitro remain of a foetal nature [6]. Despite great efforts to
improve protocols of differentiation to realise these ﬁnal steps
of maturation, limited progress has so far been made. It is possi-
ble that the ﬁnal step of maturation will only be achieved within
the extracellular niche provided by the human liver. If this were
the case then transplantation of a progenitor-like cell, which
retains the capacity to proliferate and expand in vivo, will be
essential. Unfortunately, to date there are no reports of success-
fully identifying and isolating such cells.Conclusions and future directions
Through its potential applications in developmental biology, dis-
ease modelling, and regenerative medicine, the iPS ﬁeld promises
to have a huge impact on a range of diseases that have so far been
difﬁcult to understand and even more difﬁcult to treat.
An understanding of the mechanisms controlling induced plu-
ripotency is essential for the development of better and newer
cellular reprogramming strategies, such as trans-differentiation
(the direct conversion of one adult cell type into another). This628 Journal of Hepatology 201latest form or cellular alchemy has been demonstrated to be both
possible in vitro [22–25] and in vivo [26]. It seems likely that
trans-differentiation strategies may have far quicker and wider
practical applications in clinical regenerative medicine than iPS
technology itself. The tantalizing prospect of trans-differentiating
ﬁbrosis, inducing stellate cells into healthy functional hepato-
cytes in vivo, may not be far away. If realised, this could make
the Nobel Prize winning iPS story just the opening chapter of a
book of Hepatologist’s dreams; is it ﬁnally time to take transplan-
tation into our own hands?Conﬂict of interest
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